-+ 0.00%
-+ 0.00%
-+ 0.00%
Faeth Therapeutics Enters Into Clinical Trial Collaboration And Supply Agreement With Roche To Evaluate PIKTOR In Combination With Investigational Medicine Giredestrant In Patients With HR+/HER2- Advanced Breast Cancer
Share
Listen to the news

Faeth will sponsor and conduct a Phase 1b/2 study evaluating PIKTOR, its investigational all-oral combination of serabelisib and sapanisertib, in combination with the investigational medicine giredestrant

Faeth retains all rights to PIKTOR; under the agreement, Roche will supply giredestrant for use in the study

Faeth Therapeutics (NASDAQ:FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate PIKTOR in combination with the investigational medicine giredestrant in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer.

Under the terms of the agreement, Faeth will sponsor and conduct the Phase 1b/2 study (Study FTH-PIK-101), and Roche will supply giredestrant for use in the study. Activation of the PI3K/AKT/mTOR pathway is a recognized mechanism of resistance to endocrine therapy in HR+/HER2- breast cancer, providing the rationale for evaluating PIKTOR in combination with endocrine-directed agents.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending